Mar 26, 2026 8:00am EDT Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Mar 16, 2026 8:00am EDT Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Nov 19, 2025 8:00am EST Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Jul 28, 2025 8:00am EDT Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Jul 23, 2025 8:00am EDT Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
Jun 16, 2025 8:00am EDT Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
May 29, 2025 8:00am EDT Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 19, 2025 8:00am EDT Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 13, 2025 8:00am EDT Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
